Literature DB >> 33079257

Organoid culture system for patient-derived lung metastatic osteosarcoma.

Aina He1,2, Yujing Huang3, Wanying Cheng4, Deng Zhang4, Weiwei He5, Yueqing Bai6, Chao Gu6, Zhongping Ma7, Zhenfang He7, Guifan Si7, Bing Chen7, David T Breault8, Min Dong9, Dongxi Xiang10,11.   

Abstract

Osteosarcoma (OS) is the most common primary bone malignancy with high rates of recurrence and metastasis. OS often spreads to lungs, an optimized model for studying lung metastatic OS cells may help develop potential therapies for patients with lung metastasis. Here we firstly report an organoid culture system for lung metastatic OS tissues. We provided a fully described formula that was required for establishing lung metastatic OS organoids (OSOs). Using this protocol, the lung OSOs were able to be maintained and serially propagated for at least six months; the OSOs can also be generated from cryopreserved patient samples without damaging the morphology. The patient-derived lung OSOs retained the cellular morphology and expression of OS markers (Vimentin and Sox9) that recapitulate the histological features of the human OS. The microenvironment of primary lung metastatic OSOs preserved a similar T cell distribution with the human lung OS lesions; this provided a possible condition to explore how OS cells may react to immunotherapy. OSOs established from this protocol can be further utilized for studying various aspects of OS biology (e.g., tumorigenesis and drug screen/discovery) for precision medicine.

Entities:  

Keywords:  Immunotherapy; Organoid culture; Osteosarcoma; PD-1

Mesh:

Substances:

Year:  2020        PMID: 33079257     DOI: 10.1007/s12032-020-01429-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  4 in total

1.  Establishment of Organoids From Human Epithelioid Sarcoma With the Air-Liquid Interface Organoid Cultures.

Authors:  Toru Wakamatsu; Hisataka Ogawa; Keiichi Yoshida; Yukiko Matsuoka; Kazuko Shizuma; Yoshinori Imura; Hironari Tamiya; Sho Nakai; Toshinari Yagi; Shigenori Nagata; Yoshihiro Yui; Satoru Sasagawa; Satoshi Takenaka
Journal:  Front Oncol       Date:  2022-05-23       Impact factor: 5.738

2.  Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target.

Authors:  Jun-Hua Nie; Tao Yang; Hong Li; Hai-Shan Ye; Guo-Qing Zhong; Ting-Ting Li; Chi Zhang; Wen-Han Huang; Jin Xiao; Zhi Li; Jian-Li He; Bo-Le Du; Yu Zhang; Jia Liu
Journal:  J Bone Oncol       Date:  2021-09-20       Impact factor: 4.072

Review 3.  Organoids: A New Chapter in Sarcoma Diagnosis and Treatment.

Authors:  Iason Psilopatis; Stefania Kokkali; Kostas Palamaris; Antonia Digklia; Kleio Vrettou; Stamatios Theocharis
Journal:  Int J Mol Sci       Date:  2022-09-24       Impact factor: 6.208

4.  Frequently expressed glypican-3 as a promising novel therapeutic target for osteosarcomas.

Authors:  Jun-Hua Nie; Tao Yang; Hong Li; Sheng Li; Ting-Ting Li; Hai-Shan Ye; Meng-Di Lu; Xiao Chu; Guo-Qing Zhong; Jie-Long Zhou; Mo-Li Wu; Yu Zhang; Jia Liu
Journal:  Cancer Sci       Date:  2022-08-21       Impact factor: 6.518

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.